(Q34979790)

5 August 2017

1 reference

title

Adjuvant therapy of malignant melanoma. (English)

1 reference

5 August 2017

Molife R

1

1 reference

PubMed ID

12399001

5 August 2017

Hancock BW

series ordinal

2

1 reference

5 August 2017

1 October 2002

1 reference

Critical Reviews in Oncology Hematology

5 August 2017

1 reference

5 August 2017

44

1 reference

5 August 2017

1

1 reference

5 August 2017

81-102

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

5 August 2017

1 reference

7 January 2021

The annual risk of melanoma progression. Implications for the concept of cure

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

A new American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant chemotherapy of malignant melanoma. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Treatment of melanoma by isolation-perfusion technique

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Thirty-five years of isolated limb perfusion for melanoma: indications and results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Hyperthermic perfusion with chemotherapy for melanoma of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

The role of adjuvant therapy in melanoma management

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

New approaches in metastatic melanoma: biological and molecular targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. A randomized, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Role of radiation therapy in the management of cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Locally advanced melanoma: results of postoperative hypofractionated radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

TISSUE CHANGES FOLLOWING DEPRIVATION OF FAT-SOLUBLE A VITAMIN

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Characterization of the Inhibitory Effects of Retinoids on the In Vitro Growth of Two Malignant Murine Melanomas2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Does Transfer Factor Act Specifically or as an Immunologic Adjuvant?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant immunotherapy of high risk stage I melanoma with transfer factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant immunotherapy with transfer factor in patients with melanoma metastatic to lung

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Randomized controlled trial of transfer factor in stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Levamisole in advanced human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Levamisole as adjuvant therapy for melanoma: quo vadis?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

BCG immunotherapy of malignant melanoma: summary of a seven-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Immunotherapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant immunotherapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

BCG immunotherapy in stage I melanoma patients. Does it influence prognosis determined by HLA-DR expression in high-risk primary tumors?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Inhibition of Tumour Growth by Administration of Killed Corynebacterium parvum

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

The adjuvant effect of Corynebacterium parvum: T-cell dependence of macrophage activation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Mechanisms of macrophage activation by Corynebacterium parvum. I. In vitro experiments

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Mechanisms of macrophage activation by corynebacterium parvum. II. In vivo experiments

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Comparison of the potentiation of specific tumor immunity in mice by Corynebacterium parvum or BCG

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Vaccine therapy for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Controlled trial of active immunotherapy in management of stage IIB malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Virus interference. I. The interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules .

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Treatment of metastatic malignant melanoma with recombinant interferon alpha 2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Results of adjuvant interferon study in WHO melanoma programme

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant interferon-alpha in malignant melanoma: current status

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

The role interferon-alpha in malignant melanoma remains to be defined

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

Adjuvant interferon in melanoma - a resurrection?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900014-8

7 January 2021

10.1016/S1040-8428(02)00014-8

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12399001